A STUDY OF PHARMACOLOGY OF 17-HYDROXYPROGESTERONE CAPROATE IN PREGNANCY

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这是一项由NICHD资助的多中心研究，由产科药理研究单位(OPRU)网络进行，以确定17-OHPC在怀孕期间的药理学：其药代动力学、代谢和药物的胎盘转运。17-OHPC用于预防早产。将对60名孕妇在怀孕期间进行三次研究(两项PK研究和胎盘研究 分娩过程中的运输)，以及可选的第四项研究。GU现场将有15名参与者。参与者将从注册到怀孕35周每周接受17-OHPC肌注，参与研究的时间约为15周。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a multi-center NICHD funded study, conducted by the Obstetrical Pharmacology Research Unit (OPRU) network, to define the pharmacology of 17-OHPC in pregnancy: its pharmacokinetics, metabolism and placental transport of the drug. 17-OHPC is used to prevent preterm labor. Sixty pregnant women will be studied three times during their pregnancies (two PK studies, and placental transport during labor & delivery), along with an optional fourth study. There will be 15 participants at the GU site. Participants will receive weekly IM injections of 17-OHPC from enrollment until 35 weeks gestation, with length of participation in study about 15 weeks.